KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Non Operating Income readings, the most recent being $1.1 million for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 10.94% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 56.49% decrease, with the full-year FY2025 number at $3.5 million, down 56.49% from a year prior.
  • Non Operating Income hit $1.1 million in Q4 2025 for Esperion Therapeutics, up from $677000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $3.9 million in Q4 2021 to a low of $9000.0 in Q2 2021.
  • Median Non Operating Income over the past 5 years was $1.1 million (2023), compared with a mean of $1.2 million.
  • The widest YoY moves for Non Operating Income: up 16312.5% in 2021, down 96.2% in 2021.
  • Esperion Therapeutics' Non Operating Income stood at $3.9 million in 2021, then crashed by 65.6% to $1.4 million in 2022, then dropped by 20.3% to $1.1 million in 2023, then increased by 11.76% to $1.2 million in 2024, then fell by 10.94% to $1.1 million in 2025.
  • The last three reported values for Non Operating Income were $1.1 million (Q4 2025), $677000.0 (Q3 2025), and $666000.0 (Q2 2025) per Business Quant data.